StockCall.com Provides Stock Research on Hospira Inc., Alkermes plc, Celsion Corp., Theravance Inc., and Chelsea Therapeutics International Ltd.
New York City, New York -- (May 13, 2013)
President Obama’s Affordable Care Act (ACA), which was upheld by the Supreme Court last year, is expected to have a significant impact on the healthcare sector. While the ACA is likely to result in higher costs for the healthcare sector in the near-term, an increase in the number of insured individuals will ultimately benefit the sector. Another major development in the healthcare sector, that is having an impact on drug manufacturers and biotechnology companies, is the expiration of patents on several blockbuster drugs. This has resulted in increasing competition from generic drug makers. On Friday, the healthcare sector ended sharply higher, tracking gains in the broad market. Among the major movers in the sector were Hospira Inc. (NYSE: HSP), Alkermes Plc (NASDAQ: ALKS), Celsion Corporation (NASDAQ: CLSN), Theravance Inc. (NASDAQ: THRX), and Chelsea Therapeutics International Ltd. (NASDAQ: CHTP). StockCall professionals have completed their technical analysis on HSP, ALKS, CLSN, THRX, and CHTP and these free reports are accessible by registering at
www.stockcall.com/research
Shares of Hospira Inc. edged higher in trading on Friday, extending their gains from previous trading sessions. The stock traded between $34.42 and $34.75 before finishing the day 0.20% higher at $34.62 on volume of 880,990. Hospira’s shares have gained more than 5.50% in the last three sessions. Year-to-date, the stock has gained more than 10.80% as compared to a gain of over 14.50% for the S&P 500. Shares of HSP are currently trading above their 50-day and 200-day moving averages which is a bullish signal. Sign up for the free technical research on HSP at
www.StockCall.com/HSP051313.pdf
Shares of Alkermes Plc rallied in Friday’s trading session. The stock closed 4.31% higher at $31.20 on volume of 1.20 million after touching an intra-day high of $31.35. Alkermes’ shares have had an excellent run so far in 2013, gaining nearly 68.50%. However, the stock’s MACD chart suggests that market sentiment has turned bearish. The company’s shares currently face resistance at around $32. Be sure to read our latest technical research on ALKS by registering at
www.StockCall.com/ALKS051313.pdf
Another major gainer in the healthcare sector on Friday was Celsion Corporation. Shares of the Lawrenceville, New Jersey-based company rose 4.29% to finish the day $0.970 on above average volume of 1.94 million. Despite the gains seen on Friday, shares of CLSN have fallen more than 5.70% in the last three trading sessions. Year-to-date, the stock has fallen more than 88.10%. The huge losses this year are mainly due to the sell-off seen in January. Sign up and read the complimentary report on CLSN at
www.StockCall.com/CLSN051313.pdf
Shares of Theravance Inc. soared in Friday’s trading session, touching a 52-week high of $35.80. The stock closed 11.59% higher at $34.94 on above average volume of 4.68 million. Year-to-date, the company’s shares have gained 57.10%, easily outperforming the broad market. The stock is currently trading well above its 50-day and 200-day moving averages which is a bullish signal. Theravance’s shares currently face resistance at around $35. The free report on THRX can be downloaded by signing up now at
www.StockCall.com/THRX051313.pdf
Shares of Chelsea Therapeutics International Ltd. edged lower in trading on Friday even as the broad market rose. The stock fell to an intraday low of $1.85 before finishing the day 1.06% lower at $1.86 on volume of 477,723. Shares of CHTP have traded sideways in the last two months, struggling to break through $2 resistance level. However, year-to-date, the stock is still up more than 144.70%. Free report on CHTP can be accessed by registering at
www.StockCall.com/CHTP051313.pdf
About StockCall.com
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at
www.stockcall.com
Contact Person:
William T. Knight
Email: info@stockcall.com
Contact Number: (646) 396-9857 (9:00 am EST – 01:30 pm EST)